What is this?
cGMP TGA and DSC measure mass change and heat flow under controlled temperature programs to evaluate water/solvent loss, melting, crystallization, glass transition, polymorphic transitions, degradation, and thermal fingerprints.
Start with the regulated decision
Use thermal methods for melting, desolvation, dehydration, glass transitions, polymorph conversion, degradation, and material control.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.
Overview of cGMP Thermal Analysis by TGA and DSC Services
When is it used?
Use it when specifications or investigations require thermal identity, moisture/solvent-related behavior, polymorph screening support, amorphous content, stability interpretation, or raw-material qualification.
What are limitations?
Thermal events can overlap, heating can create artifacts, and mass loss does not prove water or solvent identity without KF, MS, FTIR, XRPD, Raman, or other confirmation.
What sample amounts are needed?
Many DSC/TGA runs use small milligram-scale samples, but cGMP method development and validation need replicate material and representative lots.
What techniques compete with it?
KF, DVS, XRPD, Raman/FTIR, microscopy, ssNMR, chromatography, and evolved-gas analysis compete or complement thermal methods.
What does FDA care about?
FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic uses cGMP thermal analysis when DSC or TGA results must support regulated decisions about solid form, hydration, solvation, residual volatile content, amorphous/crystalline balance, stability, or material comparability. Real-world applications include release or stability methods, validated or verified thermal procedures, investigation support, and controlled reporting that links thermal events to quality-relevant material attributes.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for cGMP Thermal Analysis by TGA and DSC
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Thermogravimetric analysis | TA Instruments Q50 and TA Discovery 5500 TGA systems | Mass-loss, moisture/volatile content, decomposition, oxidative stability, and residue/composition analysis. |
| TGA-IR evolved-gas analysis | TA TGA with Thermo Nicolet 6700 IR interface; DTGS detector; gas cell to 250 °C; transfer line to 225 °C; nitrogen or helium purge | Evolved-gas identification, volatile/decomposition-product interpretation, and coupling of weight-loss events to IR spectra. |
| TGA software | Thermal Advantage Release 5.5.3; TRIOS v.4.3.1.39215 for Discovery 5500 workflows | Thermal-method acquisition, processing, reporting, and data review. |
| Differential scanning calorimetry | TA Instruments Q2000 and Q2500 Discovery DSC systems | Melting, crystallization, glass transition, heat capacity, compatibility, and transition-enthalpy measurements. |
| Modulated DSC capability | TA Discovery DSC configuration with modulated DSC support | Separation of overlapping reversible/non-reversible events and improved amorphous-content / glass-transition interpretation. |
| DSC software | Thermal Advantage Software v.5.5.3 | DSC acquisition and thermal-event analysis for cGMP and non-GMP workflows. |
Kofler Hot-Stage Microscopy and Thermal Event Interpretation
This example shows why visual thermal evidence can be useful when DSC or TGA events overlap or require interpretation. TGA, TG-IR, DSC, microcalorimetry, and hot-stage microscopy can support moisture/volatile loss, degradation, glass transition, crystallization, melting, oxidative stability, and phase-transition questions. For cGMP methods, event assignment must be tied to the intended quality attribute and supported by orthogonal methods where form identity matters.
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
Amorphous Content Quantitation via mDSC
Author: Triclinic Labs
Publication date: 2025
Abstract: This application note uses modulated DSC to quantify amorphous content in crystalline API by heat-capacity change at the glass transition, supporting thermal-method use for cGMP-capable material control strategies.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceParticle Size Analysis
Develop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceRelease Testing Services
Use verified or validated methods to support batch disposition, CoA issuance, stability testing, and regulatory documentation.
View serviceCommon questions
When should cGMP Thermal Analysis by TGA and DSC be run under cGMP?
Run the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
How much material should be submitted?
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.
Can Triclinic help choose the method?
Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.
What makes the result defensible?
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Do you develop, validate, and transfer DSC/TGA methods?
Yes. Triclinic develops, validates, and transfers thermal methods using DSC, TGA, TG-IR, and hot-stage microscopy where appropriate. Method work can address temperature program, atmosphere, sample mass, pan type, purge conditions, calibration, event assignment, repeatability, robustness, and transfer criteria for cGMP evaluation of melting, desolvation, dehydration, glass transition, decomposition, residual solvent, or thermal stability questions.
What makes a cGMP thermal method reproducible?
Sample mass, pan type and preparation, atmosphere, purge rate, heating or cooling profile, calibration, baseline behavior, integration rules, event definitions, and data interpretation must be controlled and justified.
Discuss cGMP testing requirements
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.